VSLRGDTRG

VSLRGDTRG is a synthetic peptide containing the RGD motif from cadherin 17 (CDH17), which binds to α2β1 integrin and activates its signaling pathway. VSLRGDTRG promotes the high-affinity conformational change of β1 integrin through the RGD motif, enhancing cell adhesion and phosphorylation of FAK and ERK1/2, thereby driving tumor proliferation and metastasis. VSLRGDTRG can be used in research on cancers expressing CDH17, such as colon cancer and pancreatic cancer[1][2].

2027476-29-3

12352209

ERK; FAK; Integrin

Cytoskeleton; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

COVID-19-immunoregulation

Cancer; Inflammation/Immunology

CC(C)[C@H](N)C(N[C@@H](CO)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@H](C(NCC(O)=O)=O)CCCNC(N)=N)=O)=O)=O)=O)=O)=O)=O

C38H69N15O14

960.05

[1]Bartolome R A, et al. An RGD motif present in cadherin 17 induces integrin activation and tumor growth[J]. Journal of Biological Chemistry, 2014, 289 (50) : 34801-34814.|[2]Jose Ignacio CASAL ALVAREZ, et al. Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif. Patent, WO2016169581A1, 2016-10-27.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P10941/

Peptides

No Development Reported